[Special Stock] Growing Attention on Beauty Medical Devices... LaserOptek Shows Strength

As of 10:10 AM on the 21st, LaserOptek, a manufacturer of skin beauty and disease treatment medical devices, is recording 11.06% higher at 10,240 KRW compared to the previous closing price in the KOSDAQ market. The sharp rise in Classys' stock price, which was rumored to be acquired by Samsung Electronics, seems to have raised expectations for the overall beauty medical device sector. Since entering the KOSDAQ market in December 2017, Classys' stock price has surged 30 times from the initial public offering price of 2,000 KRW to the recent 60,000 KRW range.

LaserOptek, which entered the KOSDAQ through a SPAC listing in February last year, recorded sales of 33.8 billion KRW and an operating profit of 1 billion KRW last year. The company aims to surpass 40 billion KRW in sales this year and reach 80 billion KRW by 2027.

LaserOptek produces skin beauty medical devices such as 'Piccolo' and 'Piccolo Premium,' which function for skin regeneration induction, scar treatment, and pore improvement, as well as disease treatment devices like 'Palace' and 'Palace Premium,' which treat vitiligo, psoriasis, and atopic dermatitis based on solid UVB laser technology. As of last year, the sales ratio was 74% for skin beauty medical devices and 14% for treatment devices.

Recently, it has attracted attention in the skin beauty sector like Classys. At the end of last month, the stock price jumped after announcing that Piccolo Premium had obtained approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) following its entry into the US, Europe, and Taiwan markets.

Hana Securities, the lead underwriter, analyzed that disease treatment devices are noteworthy because there are few competitors, the technological barriers are high, and the unit price is about three times higher. Palace Premium, which received FDA approval for psoriasis, vitiligo, and atopic dermatitis, officially started marketing at the American Academy of Dermatology in March last year. The world's first vascular treatment device, Raman Laser, can treat vascular lesions (such as rhinophyma, facial flushing, spider veins, hemangiomas, etc.). It is scheduled for domestic release this year and global release including the US next year. The laser-based urolithiasis treatment device, Thulium Fiber, is expected to be launched in 2027.